Aclaris Therapeutics has entered an exclusive licensing deal with Biosion for two antibodies, BSI-045B for atopic dermatitis ...

New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, ...

VBI Vaccines is recalling PreHevbrio and shutting down operations amid bankruptcy. Despite FDA approval in 2021, the ...

Lindis Biotech has licensed Korjuny (catumaxomab) to Pharmanovia for malignant ascites, offering a targeted immune therapy ...

Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it ...

UK pharma major GSK today announced positive headline results of GLISTEN, the ongoing global Phase III clinical trial ...

Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates.

AbbVie says that Elahere is the first and only folate receptor alpha (FRɑ)-directed antibody drug conjugate (ADC) medicine ...

UK clinical-stage gene specialist Silence Therapeutics (Nasdaq: SLN) yesterday presented end-of-treatment data from its Phase ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) on Monday approved the medicine Filspari (sparsentan) from Vifor France to treat primary immunoglobulin A nephropathy (IgAN).

New York-based ophthalmic technology company Eyenovia is considering its options. Shares in the company dropped by 70% on ...

Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to ...